Do analysts prefer CLWT or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Euro Tech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CLWT or BGLC?

Euro Tech has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Euro Tech $13.27M 0.75 $160K N/A N/A BioNexus Gene Lab $7.43M 0.49 -$2.98M -$1.26 N/A

Does the media refer more to CLWT or BGLC?

In the previous week, Euro Tech and Euro Tech both had 1 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.32 beat Euro Tech's score of 0.63 indicating that BioNexus Gene Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Euro Tech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNexus Gene Lab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BGLC or JBDI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 JBDI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BGLC or JBDI?

JBDI has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNexus Gene Lab $7.43M 0.49 -$2.98M -$1.26 N/A JBDI $8.52M 1.12 $120K N/A N/A

Does the media prefer BGLC or JBDI?

In the previous week, BioNexus Gene Lab and BioNexus Gene Lab both had 1 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.32 beat JBDI's score of -0.91 indicating that BioNexus Gene Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNexus Gene Lab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive JBDI 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend INEO or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INNEOVA 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, INEO or BGLC?

INNEOVA has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INNEOVA $58.42M 0.12 -$400K N/A N/A BioNexus Gene Lab $7.43M 0.49 -$2.98M -$1.26 N/A

Do analysts rate MWG or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Multi Ways 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, MWG or BGLC?

Multi Ways has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Multi Ways $44.77M 0.16 $1.79M N/A N/A BioNexus Gene Lab $7.43M 0.49 -$2.98M -$1.26 N/A

Do analysts rate SOS or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, SOS or BGLC?

BioNexus Gene Lab has lower revenue, but higher earnings than SOS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SOS $154.29M 0.03 -$97.32M N/A N/A BioNexus Gene Lab $7.43M 0.49 -$2.98M -$1.26 N/A

Is SOS or BGLC more profitable?

SOS has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. SOS's return on equity of 0.00% beat BioNexus Gene Lab's return on equity. Company Net Margins Return on Equity Return on Assets SOS N/A N/A N/A BioNexus Gene Lab -82.38% -32.92% -29.75%

BioNexus Gene Lab (BGLC) Competitors

$1.25 -0.02 (-1.89%)

Closing price 10/2/2026 03:58 PM Eastern

Extended Trading

$1.20 -0.05 (-3.85%)

As of 07:56 AM Eastern

Compare

BGLC vs. CLWT, JBDI, INEO, MWG, and SOS

Should you buy BioNexus Gene Lab stock or one of its competitors? BioNexus Gene Lab's main competitors and comparable companies include Euro Tech (CLWT), JBDI (JBDI), INNEOVA (INEO), Multi Ways (MWG), and SOS (SOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does BioNexus Gene Lab compare to Euro Tech?

Euro Tech (NASDAQ:CLWT) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Euro Tech has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.22, meaning that its stock price is 322% more volatile than the broader market.

Euro Tech has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. Euro Tech's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Euro Tech	N/A	N/A	N/A
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Euro Tech	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

2.9% of Euro Tech shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 79.0% of Euro Tech shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Euro Tech and Euro Tech both had 1 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.32 beat Euro Tech's score of 0.63 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Euro Tech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNexus Gene Lab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Euro Tech has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Euro Tech	$13.27M	0.75	$160K	N/A	N/A
BioNexus Gene Lab	$7.43M	0.49	-$2.98M	-$1.26	N/A

Summary

Euro Tech beats BioNexus Gene Lab on 8 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to JBDI?

BioNexus Gene Lab (NASDAQ:BGLC) and JBDI (NASDAQ:JBDI) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, BioNexus Gene Lab and BioNexus Gene Lab both had 1 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.32 beat JBDI's score of -0.91 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNexus Gene Lab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
JBDI	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
JBDI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioNexus Gene Lab has a beta of 4.22, suggesting that its stock price is 322% more volatile than the broader market. Comparatively, JBDI has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market.

JBDI has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.49	-$2.98M	-$1.26	N/A
JBDI	$8.52M	1.12	$120K	N/A	N/A

JBDI has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. JBDI's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%
JBDI	N/A	N/A	N/A

Summary

JBDI beats BioNexus Gene Lab on 6 of the 10 factors compared between the two stocks.

How does BioNexus Gene Lab compare to INNEOVA?

INNEOVA (NASDAQ:INEO) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

INNEOVA has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.22, meaning that its stock price is 322% more volatile than the broader market.

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INNEOVA	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INNEOVA has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. INNEOVA's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INNEOVA	N/A	N/A	N/A
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

INNEOVA has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INNEOVA	$58.42M	0.12	-$400K	N/A	N/A
BioNexus Gene Lab	$7.43M	0.49	-$2.98M	-$1.26	N/A

In the previous week, BioNexus Gene Lab had 1 more articles in the media than INNEOVA. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for INNEOVA. BioNexus Gene Lab's average media sentiment score of 1.32 beat INNEOVA's score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Overall Sentiment
INNEOVA	Neutral
BioNexus Gene Lab	Positive

Summary

BioNexus Gene Lab beats INNEOVA on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Multi Ways?

Multi Ways (NYSE:MWG) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Multi Ways has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.22, indicating that its stock price is 322% more volatile than the broader market.

Multi Ways has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. Multi Ways' return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Multi Ways	N/A	N/A	N/A
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

Multi Ways has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Multi Ways	$44.77M	0.16	$1.79M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.49	-$2.98M	-$1.26	N/A

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Multi Ways. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Multi Ways. BioNexus Gene Lab's average media sentiment score of 1.32 beat Multi Ways' score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Overall Sentiment
Multi Ways	Neutral
BioNexus Gene Lab	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Multi Ways	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.8% of Multi Ways shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BioNexus Gene Lab beats Multi Ways on 7 of the 12 factors compared between the two stocks.

How does BioNexus Gene Lab compare to SOS?

SOS (NYSE:SOS) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

SOS has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. SOS's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOS	N/A	N/A	N/A
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioNexus Gene Lab had 1 more articles in the media than SOS. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for SOS. BioNexus Gene Lab's average media sentiment score of 1.32 beat SOS's score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Overall Sentiment
SOS	Neutral
BioNexus Gene Lab	Positive

1.9% of SOS shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 2.7% of SOS shares are held by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioNexus Gene Lab has lower revenue, but higher earnings than SOS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOS	$154.29M	0.03	-$97.32M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.49	-$2.98M	-$1.26	N/A

SOS has a beta of 2.67, indicating that its stock price is 167% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.22, indicating that its stock price is 322% more volatile than the broader market.

Summary

BioNexus Gene Lab beats SOS on 6 of the 11 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$3.65M	$9.69B	$10.29B	$13.26B
Dividend Yield	N/A	3.39%	96.63%	17.33%
P/E Ratio	-0.99	44.03	26.65	26.04
Price / Sales	0.49	23.51	270.33	91.95
Price / Cash	N/A	49.34	24.04	34.69
Price / Book	0.35	3.87	4.82	6.34
Net Income	-$2.98M	$381.69M	$614.98M	$381.61M
7 Day Performance	-4.15%	0.06%	0.06%	-0.73%
1 Month Performance	-12.81%	0.48%	-2.57%	-4.68%
1 Year Performance	-76.45%	9.39%	2.70%	1.58%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.6482 of 5 stars	$1.25 -1.9%	N/A	-76.4%	$3.65M	$7.43M	N/A	19	Positive News
CLWT Euro Tech	1.3207 of 5 stars	$1.38 flat	N/A	-2.3%	$10.28M	$13.27M	N/A	24	Positive News
JBDI JBDI	0.1984 of 5 stars	$1.10 +2.8%	N/A	-67.6%	$10.18M	$8.52M	N/A	99	Gap Down
INEO INNEOVA	N/A	$0.61 +1.7%	N/A	-40.2%	$7.27M	$58.42M	N/A	N/A	Positive News
MWG Multi Ways	N/A	$1.31 +0.8%	N/A	-51.9%	$6.72M	$44.77M	N/A	56	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. CLWT, JBDI, INEO, MWG, and SOS

How does BioNexus Gene Lab compare to Euro Tech?

Summary

How does BioNexus Gene Lab compare to JBDI?

Summary

How does BioNexus Gene Lab compare to INNEOVA?

Summary

How does BioNexus Gene Lab compare to Multi Ways?

Summary

How does BioNexus Gene Lab compare to SOS?

Summary

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. CLWT, JBDI, INEO, MWG, and SOS

How does BioNexus Gene Lab compare to Euro Tech?

Which has more risk and volatility, CLWT or BGLC?

Is CLWT or BGLC more profitable?

Do analysts prefer CLWT or BGLC?

Do institutionals and insiders hold more shares of CLWT or BGLC?

Does the media refer more to CLWT or BGLC?

Which has better valuation and earnings, CLWT or BGLC?

Summary

How does BioNexus Gene Lab compare to JBDI?

Do institutionals & insiders hold more shares of BGLC or JBDI?

Does the media prefer BGLC or JBDI?

Do analysts rate BGLC or JBDI?

Which has more volatility and risk, BGLC or JBDI?

Which has higher valuation & earnings, BGLC or JBDI?

Is BGLC or JBDI more profitable?

Summary

How does BioNexus Gene Lab compare to INNEOVA?

Which has more risk & volatility, INEO or BGLC?

Do insiders & institutionals believe in INEO or BGLC?

Do analysts recommend INEO or BGLC?

Is INEO or BGLC more profitable?

Which has higher valuation and earnings, INEO or BGLC?

Does the media favor INEO or BGLC?

Summary

How does BioNexus Gene Lab compare to Multi Ways?

Which has more volatility & risk, MWG or BGLC?

Is MWG or BGLC more profitable?

Which has preferable valuation and earnings, MWG or BGLC?

Does the media prefer MWG or BGLC?

Do analysts rate MWG or BGLC?

Do insiders & institutionals believe in MWG or BGLC?

Summary

How does BioNexus Gene Lab compare to SOS?

Is SOS or BGLC more profitable?

Do analysts rate SOS or BGLC?

Does the media favor SOS or BGLC?

Do institutionals and insiders believe in SOS or BGLC?

Which has stronger earnings & valuation, SOS or BGLC?

Which has more risk and volatility, SOS or BGLC?

Summary

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools